MK-1084-001
A Study of Calderasib in KRAS Mutant Advanced Solid Tumors
Recruiting
Trial purpose
This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT05067283
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Advanced Solid Tumors
Age Range
18+
Sex
Male/Female
About the trial
Current trial Phase
Phase 1
Investigational medication is tested for safety on a relatively small group of 20 to 100 volunteers who are usually healthy, but not always. Phase 1 trials may happen in a doctor’s office or a hospital.
Trial start and end dates
- Trial start date 12-17-2021
- Estimated primary completion date 02-25-2030
- Estimated trial completion date 02-25-2030
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.